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Introduction

Stroke is one of the leading causes of lower-limb hemiplegia: a long-term disability
involving paralysis of one side of the body (Donkor 2018). Although 80% of stroke patients tend
to regain some ambulatory function post-stroke, many patients are still left with major gait deficits
that reduce quality of life and may lead to falls or other potential injury (Baumann et al. 1992,
Baronchelli et al. 2021).
Conventional physiotherapy for gait recovery involves overground or treadmill walking
exercises in the presence of one or more physical therapists, often with overhead body-weight
support if needed by the patient (Moseley et al. 2005). The repetitive task of walking allows for
proper, symmetrical gait cycling to be recovered in patients with hemiplegia (French et al. 2009).
An issue with the conventional set-up involving overground or treadmill walking is the amount of
burden placed on the present physiotherapist, who may be attempting to manually correct
asymmetrical weight shifting or gait cycling (Hesse et al. 2003). Conventional gait exercises can
also be incredibly limiting in their effectiveness in severely disabled stroke patients, who may not
be able to ambulate without the assistance of multiple physiotherapists (Mehrholz et al 2017).
Recently, automated electromechanical devices have gained attention as an alternative to
conventional overground or treadmill-based gait training. Robotic-assisted devices for gait
recovery have been shown to reduce the manual strain on physiotherapists, allow for greater
repetition of steps taken and total walked distance during a training session, and quantitively track
improvements throughout the duration of a treatment intervention (Mehrholz et al. 2018).

3
There are several robotic gait training models that have been explored in literature and have
even become commercially available for use in a clinical setting. Exoskeletons consist of an
individualized orthosis that mechanically actuates lower-limb joints during ambulation (Hesse et
al 2008). Exoskeletons may be static or fixed to a treadmill setting, such as the Lokomat® (Hidler
et al. 2008), or mobile for use in an overground setting, such the Hybrid Assistive Limb® (Nilsson
et al. 2014) or H2 robots (Bortole et al. 2015). End-effector systems, such as the G-EO system
(Vallasciani et al. 2014) or Morning Walk® (Kim et al. 2018), provide assisted ambulation via
treadmill footplates, allowing the hip and knee joints to move freely (Hesse et al. 2008). Cabledriven gait trainers deliver mechanical assistance to the lower limb using a pulley-based cable
system (Wu et al. 2011). Previously conducted meta-analyses found significant evidence on how
gait training with a robotic device leads to substantial improvements in walking ability in stroke
patients, demonstrating their potential for mainstream use in gait-recovery therapy (Moucheboueff
et al. 2020, Bruni et al. 2018). However, few clinical trials have compared the effects of robotic
gait training to normal physical therapy. Such research is important to determining the clinical
significance and placement of robotic-assisted gait training in a rehabilitative setting.
Meta-analyses have been conducted on the comparative effects of robotic gait training
interventions and conventional physiotherapy in stroke-recovery patients. Mehrholz et al.
conducted several meta-analyses in 2007, 2012, and 2017 that have looked at the effects of
electromechanically assisted gait training relative to normal care patients. All three studies have
displayed moderate-quality evidence that mechanically assisted gait training may improve gait
recovery in stroke patients more significantly than conventional physical therapy. However, other
meta-analyses found that there were no perceived differences in robotically assisted gait training
relative to conventional gait therapy for subacute and chronic stroke patients in recovery (Tedla et
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al 2019, Kim 2019). These conflicting findings, as well as the limited number of reviews on this
topic, demonstrate a need for more analyses on the comparison of robotic-assisted gait training
and conventional physiotherapy for gait recovery of stroke patients.
Reviews on this topic have demonstrated significant gaps in the research for robotic gait
training in stroke patients. Previous reviews have commonly stated that more clinical trials with
long-term follow-ups, blinding, and group randomization are needed in the field of robotic-assisted
clinical gait training (Tedla et al. 2019, Bruni et al. 2018, Molteni et al. 2018, Mehrholz et al.
2017,). Although most previous clinical trials have compared the outcome measurements of
robotic-assisted and conventional gait training, no studies have been conducted on the costeffectiveness of each of these therapeutic interventions (Mehrholz et al. 2017). A scoping review
conducted by Louie et al. demonstrated a need for more studies looking at how baseline
characteristics, such as subacute and chronic stroke differences or initial walking ability, may
affect the improvement of stroke patients undergoing robotically assisted therapy (Louie et al.
2016). Louie et al. 2016 also demonstrated several limitations with the current studies on
exoskeleton-gait training, such as small sample sizes and a lack of comparisons to normal care
groups in clinical trials. As many of these reviews identifying research gaps were published five
or more years ago, an update for such findings is needed to determine if clinical research has
addressed some of these limitations.
The purpose of this scoping review is to provide an updated examination of the range and
nature of the literature comparing robot-assisted gait training (RAGT) with conventional gait
training (CGT) for gait recovery in post-stroke subjects. This study will also determine if research
gaps identified in previous reviews have been addressed by clinical trials, as well as bring attention
to any new gaps that may need to be considered in future studies.
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Review Methods

This review article was done in accordance with the methods outlined by Daudt et al. 2013,
which built from the scoping review framework initially described by Arksey and O’Malley in
2005.
The databases used for this study included Web of Science and PubMed, both of which
were accessed on January 15th, 2022. Articles were searched on Web of Science with the search
phrases “Robot assisted gait training stroke” “wearable robotic gait stroke, “exoskeleton gait
stroke”, “assistive limb gait stroke”, “exoskeleton gait training stroke”, “exosuit gait stroke”
robotic gait stroke”, and “robotic gait training stroke”. Each search phrase was entered individually
with the filters “rehabilitation” under Web of Science Categories and Publication Years “2017”,
“2018”, “2019”, “2020”, “2021”, and “2022”. The same search phrases were used in the advanced
search engine setting of the PubMed database, such that the search criteria resembled as follows:
(robot assisted gait training stroke) OR (wearable robotic gait stroke) OR (exoskeleton gait stroke)
OR (assistive limb gait stroke) OR (exoskeleton gait training stroke) OR (exosuit gait stroke) OR
(robotic gait stroke) OR (robotic gait training stroke). These phrases were searched with the
“Results by Year” filter such that only articles from 2017-2022 were included. In addition, the
filters to screen for “Randomized Controlled Trials” and “Clinical Trials” under “Article Type”
were also applied.
The inclusion criteria for this study included full-text, peer reviewed articles on randomized
clinical trials for gait recovery in post-stroke patients at any stage (acute, subacute, chronic). Each
article needed to include adult (≥18 yoa) subjects randomly placed into one of two side-by-side
experimental groups: a conventional physiotherapy (CGT) group and a robotic-assistance gait
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training (RAGT) group. The RAGT group included any set of adult post-stroke subjects that
underwent a gait training regime including the use of a wearable device that provided active,
mechanical assistance to the lower extremities. The goal of the robotic device used in each RAGT
group was to emulate or recover a healthy gait cycle in a hemiplegic, stroke patient. Some viable
examples encountered in this screening included exoskeletons with motor-actuated joints, endeffector robots, and treadmill-based devices that provided motor assistance via cables.
Conventional gait training groups included any set of post-stroke subjects that received a gait
training regime with the presence and guidance of a licensed physiotherapist with the goal of
recovering a healthy gait cycle. Studies were included if the subject groups were non-mixed
diagnosis and contained only post-stroke patients suffering from hemiplegia or hemiparesis in the
lower extremities due to an ischemic or hemorrhagic stroke. This study also focused solely on
articles including one of six clinical outcome measurements: Functional Ambulatory Categories,
Fugl-Meyer Assessment-Lower Extremity, 6-minute Walking Distance, 10-meter Walk Speed,
Berg Balance Scale, and Modified Ashworth Scale. These measurements were chosen based on
their high reliability and validity (Holden et al. 1984, Mehrholz et al. 2007, Dunn et al. 2015,
Cheng et al. 2020, Berg et al. 1995, Park et al. 2014, Ghotbi et al. 2009), frequency of use in
clinical studies of stroke subjects, and the literature demonstrating the minimal clinically important
difference necessary for recovery-phase stroke patients (Perera et al. 2006, Tang et al. 2012, Tilson
et al. 2010, Tamura et al. 2021, Pandian et al. 2016, Chen et al. 2020). Minimal clinically important
differences for individual outcome measures are included in Table 1, as demonstrated by
surrounding literature.
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Table 1) Minimal clinically important differences (MCID) of functional outcome measures as demonstrated by cited
literature

Outcome
Measure
Subacute Stroke Subjects
FAC +1 (Holden et al.)
6MWT +20.0 m [small] (Perera et al.),
10mWS/
Gait Speed
BBS
FMA-LE
MAS-LL

+49 m [moderate] (Perera et al.)
+0.06 m/s [small] (Perera et al.)
+0.14 m/s [moderate] (Perera et al.)
+0.16 m/s [substantial] (Tilson et al)
+5 pts [substantial] (Tamura et al.)
N/A
+0.45 pts [moderate] (Chen et al.)
+0.73 pts [substantial] (Chen et al.)

Chronic Stroke Subjects
+1 (Holden et al.)
+34.4 m (Tang et al)
N/A

N/A
+6 pts (Pandian et al.)
+0.45 pts [moderate] (Chen et al.)
+0.73 pts [substantial] (Chen et al.)

Exclusion criteria included studies that were non-randomized or did not have a
conventional physiotherapy experimental group for comparison with a robotic-assistance group.
Studies that focused on electromyography, spatiotemporal gait kinematics, and metabolic costs
without the accompanying use of one of the clinical outcome measurements listed in the inclusion
criteria were also excluded. Studies with participant subsets including mixed-diagnosis groups,
healthy, non-recovery phase subjects, upper-extremity robotic devices, or the co-administration of
an experimental medication alongside robotic-device treatment or conventional physiotherapy
were not considered for analysis. Articles that contained only an abstract or a paywall when
accessed through the Portland State University Library were also excluded. Studies that focused
on the planning-phase of a robotics-based clinical trial or technology in development for gait
recovery were not considered for review.
Statistical Analyses
Basic statistical analyses were done to obtain a general idea of how effective RAGT is
relative to CGT in regard to several subject and intervention protocol characteristics. All statistical

8
tests were conducted on Microsoft Excel®. Independent, two-tailed t-tests were done to find if
there were significant differences in the inclusion of commonly listed subject characteristics. These
characteristics included gender (male/female), stroke type (ischemic/hemorrhagic), and side of
lower-limb hemiparesis (left/right). T-tests were conducted to find significant differences in
characteristics within RAGT groups, within CGT groups, and amongst all subjects included in the
reviewed studies.
Weighted mean values were conducted on outcome measurement improvement values
from the RAGT and CGT groups. This was done by multiplying the mean improvement difference
from baseline to post-intervention by the number of subjects in each study. The product of each
study including the given outcome measure was then summed. This sum-product value was then
divided by the total number of subjects across all studies including that outcome measurement to
find the mean weighted improvement. Two studies (Wall et al. 2020, Aprile et al. 2019) only
observed outcome measurements differences using median values. Louie et al. listed their
improvement difference of FAC using median values, but used mean values for 6MWT, 10mWS,
BBS, FMA-LE, and Gait speed. Mean Weighted differences were conducted including studies
with median improvement differences and excluding studies with median improvement
differences. Studies that did not conduct a baseline test for 6MWT and 10mWS (Louie et al. 2021,
Wall et al. 2020) were also excluded from mean weighted differences for these outcome measures.
Results
Screening
The electronic database searches on Web of Science and PubMed generated 183 and 94
unique titles respectively. After accounting for duplicates, 46 titles were present in both databases,
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indicating that this database search generated a total of 231 unique titles. After screening the
abstract and title of each article for inclusion/exclusion criteria, 25 articles were chosen for fulltext eligibility. Reading the articles full-text excluded 14 articles, leaving 11 articles to be included
in this study (Louie et al. 2021, Yeung et al. 2021, Kang et al. 2021, Li et al. 2021, Palmcrantz et
al. 2021, Yeon-Gyo et al. 2020, Wall et al. 2020, Stolz et al. 2019, Aprile et al. 2019, Kim et al.
2019, Watanabe et al. 2017). The screening process for this study is further detailed in Figure 1.
All studies included were published within the last five years (>2016), with seven of these studies
being published within the year 2020 (Louie et al. 2021, Yeung et al. 2021, Li et al. 2021, Kang et

Figure 1) Flow chart of the screening process for the presented review
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al. 2021, Palmcrantz et al. 2021, Yeon-Gyo 2020, Wall et al. 2020). The most common location
of study was China, accounting for three articles (Yeung et al. 2021, Li, et al. 2021, Yeon-Gyo et
al. 2020). Other locations of study included two articles from South Korea (Kang et al. 2021, Kim
et al. 2019), two articles from Sweden (Palmcrantz et al. 2021, Wall et al. 2020), and single studies
conducted in Canada (Louie et al. 2021), Australia (Stolz et al. 2019), Italy (Aprile et al. 2019),
and Japan (Watanabe et al. 2017).
Study Characteristics
Design
As stated previously, all included studies were randomized, controlled trials containing at
least an RAGT and a CGT group. Palmcrantz et al. 2021 included a third “control group”, which
included the same patient inclusion criteria as their RAGT and CGT groups but did not follow a
planned intervention with a licensed physiotherapist. Yeung et al. 2021 also included a third group
labelled as the “swing-assist ankle robot” group. This form of assistance locked the ankle-joint of
the exoskeleton during the swing stance of gait cycling in a passive-manner and was therefore not
analyzed in this study. Six studies allocated subjects from multiple hospitals and rehabilitation
centers (Louie et al. 2021, Yeung et al. 2021, Palmcrantz et al. 2021, Yeon-Gyo et al. 2020, Kim
et al. 2019, Aprile et al. 2019), while the remaining five studies pulled subjects from a single
center. Five studies were indicated to be single-blinded, assessor-blinded trials (Louie et al. 2021,
Li et al .2021, Palmcrantz et al. 2021, Yeon-Gyo et al. 2020), while three studies indicated that
assessors were not blinded to the allocation group of patients (Kang et al. 2021, Kim et al. 2019,
Watanabe et al. 2017). The remaining three studies did not specify whether assessors or subjects
were blinded to allocation groups (Yeung et al. 2021, Stolz et al. 2019, Aprile et al. 2019). Only
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Aprile et al. 2019 indicated that their trial was a pilot study. 5 studies included at least one longterm follow-up post intervention, ranging from 1 – 6 months (Louie et al. 2021, Palmcrantz et al.
2021, Wall et al. 2021, Stolz et al. 2019, Watanabe et al. 2017). Two studies included a second
post-intervention follow-up as well (Palmcrantz et al. 2021, Watanabe et al. 2017). Palmcrantz et
al. 2021 conducted a second follow up at 12 months post-intervention and Watanabe et al. 2017
conducted another follow-up 2 months post-intervention (12 weeks from initiation of study).
Robotic Devices
The broadness of criteria for the type of robotic gait trainers examined in this study allowed
for the inclusion of a wide variety of devices that provided active assistance to stroke patients. The
most common type of device examined was the powered, multi-joint exoskeleton, which was used
as the robotic gait trainer for RAGT groups in seven studies (Louie et al. 2021, Li et al. 2021, Kang
et al. 2021, Palmcrantz et al. 2021, Yeon-Gyo et al. 2020, Wall et al. 2020, Watanabe et al. 2017).
Powered, multi-joint exoskeletons deliver motor actuated assistance to more than one joint of the
lower extremity (ankle, knee, hip). These differ from single-joint exoskeletons that only actuate
one lower-extremity joint. Only Yeung et al. 2021 used a novel single-joint, powered exoskeleton
for the ankle, named the “Exoskeleton Ankle Robot”. Of the powered exoskeletons, the singlelimb Hybrid Assistive Limb® was the most studied device, which was included in three studies
(Palmcrantz et al. 2021, Wall et al 2020, Watanabe et al 2017). In all three of these studies, the
Hybrid Assistive Limb® was worn on the paretic lower limb of recovering stroke subjects. Other
powered, multi-joint exoskeletons included the BEAR-H1® (Li et al. 2021), SUBAR® (Kang et
al. 2021), EksoGT® (Louie et al. 2020), and the ExoWalk® (Yeon-Gyo et al 2020). Two studies
used an end-effector robot with body weight support that provided powered assistance through
actuated foot plates (Aprile et al 2019, Kim et al 2019). The end-effector models observed in this
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study were the G-EO System® (Aprile et al. 2019) and the Morning Walk® (Kim et al. 2019).
Stolz et al. 2019 was the only study to use a novel, cable-driven gait trainer termed the
“RoboWalk”. Six studies included a robotic device that could be initiated through voluntary user
movement (Louie et al 2021. Palmcrantz et al 2021, Yeung et al 2021, Li et al 2021, Wall et al
2020, Watanabe et al 2017). Five other studies included a device initiated by a physiotherapist and
could be adjusted using a software program (Kang et al 2021, Yeon-Gyo et al 2020, Aprile et al
2019, Stolz et al 2019, Kim et al 2019). Details on type of assistance provided and initiation of
movement of the devices used in each study are outlined in Table 2.
Participants
Inclusion criteria for post-stroke subjects focused most on stroke-recovery phase and
ambulatory ability. Three studies looked at stroke patients in the chronic phase of recovery
(Palmcrantz et al 2021, Kang et al 2021, Yeon-Gyo et al 2020). The inclusion criteria for stroke
onset in chronic phase studies was broadly ranged. Yeon-Gyo et al. 2020 included all subjects with
stroke onset >3 months, while Kang et al. 2021 looked at subjects with onset >6 months.
Palmcrantz et al. 2021 identified a range of 1-10 years since stroke onset for subjects in their
inclusion criteria. Seven studies included subjects in the subacute phase of stroke recovery (Louie
et al. 2021, Yeung et al. 2021, Li et al. 2021, Wall et al. 2020, Stolz et al. 2019, Aprile et al. 2019,
Watanabe et al. 2017). The inclusion criteria for the subacute phase studies were highly variable,
with two studies including a range of 2 weeks – 6 months as their inclusion for subacute stroke (Li
et al. 2021, Aprile et al. 2019). Five studies did not specify a lower range value for stroke onset in
their inclusion criteria but had an upper range value varying between 2 – 6 months (Louie et 2021,
Yeung et al. 2021, Wall et al. 2020, Stolz et al. 2019, Watanabe et al 2017). Kim et al. 2019 was
the only study to not include a stroke-recovery phase or time since stroke onset as part of their
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Table 2) Details on novel and commercially available robotic gait training devices used by the studies included in
this review
Robotic Gait Training
Device
EksoGT®
[Ekso Bionics]
(Louie et al. 2021)

Exoskeleton Ankle
Robot
[Novel - Yeung et al.
2017]

Device
Description
Bilateral
Multi-joint
exoskeleton

Assistance Delivered

Initiation of Movement

Active Sagittal-Plane DOF in the Hip
and Knee. Passive spring-loaded DOF
in the Ankle. Foot clearance provided
by footplate
Active Sagittal-Plane DOF in the ankle

Movement may be automatic (initiated by physical
therapist) or voluntary (initiated by user movement Weight Shift detected by Footplates

Voluntary Movement initiated by user - Gait cycling
triggered by minimal movement and detected by
algorithm synchronized with user
Automatic movement initiated by Physiotherapist.
Direction of forward movement facilitated by patient
joystick

Bilateral
Multi-joint
exoskeleton
Unilateral
Multi-joint
Exoskeleton

Active Sagittal-plane DOFs in Hip,
Knee, and Ankle. Passive
abduction/adduction DOF in Hip
Active Sagittal-plane DOF in the Hip,
Knee, and Ankle. Foot clearance
provided by footplate BWS provided by
buttocks saddle and upper trunk
pedestal
Active Sagittal plane DOFs in Hip,
Knee, and Ankle. Foot clearance
provided by footplates
Active Sagittal-plane DOFs in Hip and
Knee. Passive Sagittal-Plane DOF in the
Ankle

Treadmillbased End
Effector

Gait Actuation provided by Footplates
on a double crank and rocker. BWS
provided by overhead harness

Automatic movement initiated by Physical
therapist/Computer

Treadmillbased End
Effector
Treadmillbased Cable
Actuator

Gait Actuation provided by Footplates
on a double crank and rocker. BWS
provided by buttocks saddle
Pulley and Cable Actuation facilitate
active Knee extension, Hip flexion, and
Ankle Dorsiflexion

Automatic movement initiated by Physical
Therapist/Computer

Unilateral
Single-Joint
Exoskeleton

Voluntary Movement initiated by user movement:
Weight shift detected by pressure-activated footplate
ankle. movement detected inertial measurement
synchronized with user

(Yeung et al. 2021)

BEAR-H1®
[Milebot Robotics]
(Li et al. 2021)

SUBAR®
[Cretem]
(Kang et al. 2021)

Exowalk® [ACHMH]
(Yeon-Gyo et al. 2020)

HAL®
[Cyberdyne]
(Palmcrantz et al. 2021,
Wall et al. 2020,
Watanabe et al. 2017)

G-EO System®
[Reha Technology
AG]

Bilateral
Multi-joint
Exoskeleton
Bilateral
multi-joint
exoskeleton

Automatic movement initiated by Physiotherapist.
Direction of forward movement facilitated by patient
joystick
CAC: Automatic Movement initiated by Physical
Therapist. CVC Mode: Voluntary Movement
initiated by user - bioelectric signals detected by
electrodes, weight shift detected by footplate

(Aprile et al. 2019)

Morning Walk®
[CUREXO]
(Kim et al. 2019)

RoboWalk
[Novel - Wu et al.
2011]

Automatic movement initiated by Physical
Therapist/Computer

(Stolz et al. 2019)

inclusion criteria. Six studies included FAC as a means for inclusion (Louie et al. 2021, Yeung et
al. 2021, Kang et al. 2021, Li et al. 2021, Wall et al. 2020, Kim et al. 2019). Two studies only
included subjects with an FAC ranging from 0-1, indicating that all included subjects were nonambulatory (Louie et al. 2021, Wall et al. 2020). The remaining four studies included subjects with
an FAC >1 (Yeung, et al. 2021, Li et al. 2021, Kang et al. 2021, Kim et al. 2019). Five studies did
not directly include FAC in their inclusion criteria. However, three studies included the ability to
ambulate with or without assistance as a means for inclusion (Yeon-Gyo et al 2020, Aprile et al
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2019, Watanabe et al. 2017), while Palmcrantz et al. 2021 included the inability to walk without
manual assistance in their inclusion criteria. Six studies chose to look at adult subjects >18 yoa
(Louie et al. 2021, Kang et al. 2021, Li et al. 2021, Stolz et al. 2019, Kim et al. 2019, Aprile et al.
2019). Two of these studies capped their age range at 75 yoa (Li et al. 2021) or 80 yoa (Aprile et
al. 2019). Details on inclusion criteria are provided in Table 3.
A total of 410 post-stroke subjects participated in the 11 studies included in this article,
with 186 participants undergoing an intervention involving RAGT and 185 partaking solely in
CGT. The number of subjects included in an RAGT group ranged from 12 – 28 subjects, with the
average number of RAGT subjects per study being 16.90 persons. The number of subjects included
in a CGT group ranged from 12 – 30 subjects, with the average number of CGT subjects per study
being 16.81 persons. Across all 11 studies, the mean age of participants ranged from 50.53 – 66.9
yoa in the RAGT groups and 50.13 – 76.8 yoa in the CGT groups. Across the three chronic stroke
studies, the mean duration from time of stroke to study inclusion ranged from 168.3 – 638.7 days
in the RAGT subjects and 142.6 – 1155.8 days in the CGT subjects. Across the seven subacute
stroke studies, the mean duration from time of stroke to study inclusion ranged from 15.6 – 77.0
days in the RAGT groups and 25.5 – 102.8 days in CGT groups.
All studies included a male to female ratio of subjects allocated to each treatment group.
249 males and 117 females were allocated to either a RAGT or CT group across the 11 studies.
133 males and 56 females were allocated to an RAGT group, while 116 males and 61 females
were allocated to a CGT group. Ten studies specified which ischemic or hemorrhagic stroke-type
subjects were allocated to each treatment (Louie et al. 2021, Yeung et al 2021, Li et al 2021, Kang
et al 2021, Palmcrantz et al 2021, Yeon-Gyo et al 2020, Wall et al 2020, Kim et al 2019, Aprile et
al 2019, Stolz et al 2019). In total, 232 ischemic and 109 hemorrhagic subjects were included
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across these ten studies. 122 ischemic and 52 hemorrhagic subjects were allocated to RAGT
groups, while 110 ischemic and 57 hemorrhagic subjects were allocated to CGT. Nine studies
specified whether subjects were paretic on the left or right lower limb (Louie et al. 2021, Yeung
et al. 2021, Li et al 2021, Kang et al 2021, Palmcrantz et al 2021, Wall et al 2020, Kim et al 2019,
Aprile et al. 2019, Stolz et al 2019). Within these nine studies, 168 were paretic on the left side
and 136 were paretic on the right side. Eighty-one left-sided paretic and 75 right-sided paretic
subjects were allocated to RAGT groups while 87 left-sided paretic and 61 right-sided paretic
subjects were randomly placed in CGT groups. No significant differences were detected for
baseline characteristics between CGT and RAGT groups for gender, stroke type, or right/left
hemiparetic side in individual studies. The CGT group in Stolz et al. 2019 was found to have a
significantly lower Functional Independence Measure than subjects in the accompanying RAGT
group (p = 0.03). Subjects in the RAGT of Kim et al. 2019 were found have significantly greater
weight (p = 0.01) and height (p = 0.03) than subjects in the CGT group. These are the only instances
across all 11 studies demonstrating a significant difference in baseline characteristics.
Although subjects within individual studies did not find significant differences in the
characteristics of subjects, the independent t-test found a significant difference between the total
number of males and females included across all 11 studies (p < 0.05). Males were significantly
more prevalent than females in the total number of RAGT subjects (p = 0.0018), the total number
of CGT subjects (p = 0.0019), and total number of subjects included across all 11 studies (p =
0.0002). A significant difference was observed in the total number of ischemic and hemorrhagic
stroke subjects allocated to each group. Ischemic stroke subjects were significantly more prevalent
in RAGT groups (p = 0.0004), CGT groups (p = 0.0019), and the total number of included subjects
(p < 0.0001) than hemorrhagic stroke subjects. The independent t-test did not reveal any significant

16
differences between left and right hemiparetic stroke subjects included in the observed 11 studies
or the number of participants allocated to either an RAGT or CGT group.
Training protocols
Training interventions were highly variable between all 11 studies. Training interventions
lasted anywhere between a range of 2 – 10 weeks. The frequency of gait training sessions for both
RAGT and CGT groups ranged anywhere from 2 – 5 sessions per week. Total number of sessions
attended during intervention ranged from 10 – 24 sessions. Gait training session times lasted within
the range of 20 – 90 minutes for both RAGT and CGT groups. Eight studies focused gait training
for RAGT groups solely on use with the experimental device (Yeung et al. 2021, Li et al. 2021,
Kang et al. 2021, Wall et al 2020, Yeon-Gyo et al. 2020, Aprile et al. 2019, Kim et al. 2019,
Watanabe et al 2017). Two studies implemented a combination of robotic-assisted gait training
and conventional gait training into each session (Palmcrantz et al. 2021, Stolz et al. 2019). The
RAGT subjects from Louie et al. 2021 initially trained with robotic-assisted gait training but
allowed physical therapists to switch subjects over to conventional gait training once they reached
“a threshold level of walking independence”. Nine studies included other occupational therapy and
strengthening exercises into their treatment intervention for RAGT groups, as well as their CGT
groups (Louie et al. 2021, Yeung et al. 2021, Li et al. 2021, Palmcrantz et al. 2021, Yeon-Gyo et
al. 2020, Wall et al. 2020, Stolz et al. 2019, Aprile et al. 2019, Kim et al. 2019,). Four studies
specified using an overhead harness for Body-weight support throughout RAGT training
(Palmcrantz et al. 2021, Wall et al. 2021, Aprile et al. 2019, Watanabe et al. 2017). Overhead BWS
was slowly weaned off patients as the intervention progressed. Amongst the exoskeleton based
RAGT groups, two studies had subjects walk on a treadmill while training with the robotic device
(Palmcrantz et al. 2021, Wall et al. 2020). The remaining six exoskeleton-based studies used
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overground walking (Louie et al. 2021, Yeung et al. 2021, Kang et al. 2021, Li et al. 2021,
Watanabe et al. 2017, Yeon-Gyo et al. 2020,). Only Yeung et al. 2021 incorporated overground
stair training into their gait training protocol. Kim et al. 2019 and Aprile et al. 2019 incorporated
stair training protocols with their respective end-effector devices. Details on training protocols
from individual studies are further outlined in Table 3.
Outcome Measures
The most frequently used clinical outcome measurement was the Functional Ambulatory
Category (FAC), which was included in nine of the 11 studies (Louie et al. 2021, Yeung et al.
2021, Kang et al. 2021, Li et al. 2021, Yeon-Gyo et al. 2020, Wall et al. 2020, Aprile et al. 2019,
Kim et al. 2019, Watanabe et al. 2017). Gait speed in meters/second was measured in eight of 11
studies, typically in the form of a 10-meter Walking Test (10mWS) (Yeung et al. 2021, Kang et
al. 2021, Palmcrantz et al. 2021, Yeon-Gyo et al. 2020, Stolz et al. 2019, Aprile et al. 2019, Kim
et al. 2019) or 5-meter Walking Test (Louie et al. 2021). Walking endurance measured in total
distance walked (meters) was also measured in eight of the 11 studies, which either involved a 6minute Walking Test (Louie et al. 2021, Yeung et al. 2021, Li et al. 2021, Palmcrantz et al. 2021,
Yeon-Gyo et al. 2020, Stolz et al. 2019, Aprile et al. 2019, Watanabe et al. 2017) or a 2-minute
Walking Test (Wall et al. 2020). Balance was recorded using the Berg Balance Scale (BBS) in
seven studies (Louie et al. 2021, Yeung et al. 2021, Kang et al. 2021, Palmcrantz et al. 2021, Wall
et al. 2020, Yeon-Gyo et al. 2020, Kim et al. 2019). Motor impairment of the lower limbs in stroke
subjects was measured using the Fugl-Meyer Assessment of the Lower Limbs (FMA-LE) in five
studies (Louie et al. 2021, Li et al. 2021, Palmcrantz et al. 2021, Wall et al. 2020, Watanabe et al.
2017). Three studies used the Modified Ashworth Scale (MAS-LL) to gauge muscle spasticity of
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Table 3) Details on inclusion criteria and intervention protocol for RAGT and CGT groups from individual clinical
trials
Study

Subject Population
Size/Inclusion

Intervention
Period

RAGT Protocol

CGT Protocol

60 minutes of gait training with EksoCT. 75% of
intervention sessions focused on gait training with
EksoGT. Training done with Physiotherapists
certified (by the manufacturer) to operate EksoGT.
As training progressed, physiotherapists reduced the
assistance provided by the device and increased
walking duration. Physiotherapists were allowed to
opt subjects out of RAGT (and replace gait training
sessions with CGT) if subjects were able to
ambulate for ≥25 minutes and reach 700
steps/session by Week 4. Remaining 25% of
sessions focused on pain management, discharge
planning, and other occupational therapy exercises.
30 minutes of gait training with the novel Ankle
Exoskeleton Robot in power-assisted mode.
Training began with 10 minutes of overground
walking, following by 10 minutes of stair
ascension/descension training, followed by 10
minutes of over ground walking. One physical
therapist held on the waist band of the subject on the
hemiparetic side and provided verbal cues to aide in
training. Total training time equated to 45 minutes
including applying and removing exoskeleton. Gait
training sessions were integrated into 2-hour
physical therapy sessions.
30 minutes of Gait training with SUBAR®. Subjects
initially trained at a pace of 0.5 km/hr with a step
length 20-50 cm. Subjects reached a walking speed
of 2.5 km/hr by session 10. Step length was adjusted
at 1 cm increments.

45-60 minutes of conventional
physical therapy in the presence
of a licensed physical therapist.
Physical therapists were not
instructed on how to conduct
conventional care except to avoid
the use of robotic devices.
Protocol typically focused on gait
and mobility training.

Two 30-minute sessions/day of gait training with
BEAR-H1® guided by physical therapists. Subjects
also received routine physiotherapy in muscle
strengthening, stretching, and balancing.

Two 30-minute sessions of
Conventional gait training guided
by physical therapists per day.
Training included dynamic sitting
and standing exercises, weight
support exercises, and
conventional gai training.

Exoskeleton-Based Studies
Louie et al.
2021

•n = 36
•Subacute Stroke
•12 weeks post-stroke
•>19 yoa
•Hemiparesis
•Baseline FAC 0-1
(significant assistance
needed from a therapist
to walk)
•Ability to
communicate in
English

RAGT:
3 sessions
/week
CGT: 4-5
sessions
/week for 8
weeks.
Follow up
assessment
at 6 months
postenrollment

Yeung et
al. 2021

•n = 31
•Subacute, first-ever
stroke patients
•<2 months post-stroke
•Hemiparesis
•FAC ≥ 1 (ability to
walk with one-person
assistance)
•Cognitive ability to
follow instructions

20 total
RAGT
sessions
integrated
into 10-week
intervention

Kang et al.
2021

•n = 30
•Chronic stroke
•>6 months post-stroke
•>18 yoa
•Hemorrhagic or
ischemic stroke
•FAC > 3 (for safety
concerns)
•Previously
independent walker
•n = 35
•Subacute, first-ever
stroke
•2 weeks - 6 months
post-stroke
•18-75 yoa
•FAC ≤ 4 (limitation to
walking ability)
•Mini-mental state
examination score >24
•Cognitive ability to
sign consent form

10 total
sessions over
a 3-week
intervention

Li et al.
2021

Gait
Training
occurred 5
days/week
over 4-week
intervention

2 hours of conventional therapy
prescribed by a team of physical
therapists. Protocol of
conventional physical therapy
included lower-limb exercises for
standing, stepping, balance, and
gait training.

30 minutes of conventional
physical therapy based on
"traditional neurodevelopmental
treatment techniques” (Kang et al.
2021). Subjects typically
practiced functional gait training,
muscle strengthening, sitting to
standing movements, and active
range of motion exercises.

19
Table 3 cont.)
Study
Palmcrantz
et al. 2021

Yeon-Gyo
et al. 2020

Wall et al.
2020

Watanabe
et al. 2017

Subject Population
Size/Inclusion
•n = 28
•Chronic stroke
•1-10 years post-stroke
•Previously received
conventional
intervention related to
hemiparesis of the
lower extremities
•Ischemic or
hemorrhagic stroke
•Ability to walk with
manual support
•Compatibility with
HAL suit (Height >
150 cm, Weight < 100
kg)
•n = 38
•Chronic stroke
•>3 months post-stroke
•Hemiparesis due to
stroke
•Ability to ambulate
with or without
assistance from one
other person

•n = 32
•Subacute Stroke
•<8 weeks post-stroke
•Hemorrhagic or
ischemic stroke
•FAC ≤ 1 (inability to
walk continuous
without manual support
•Ability to maintain
sitting posture for >5
minutes
•n = 24
•Subacute stroke
•<6 months post-stroke
•Unilateral
hemorrhagic or
ischemic stroke
•Hemiparesis due to
stroke
•FAC < 4
•Ability to ambulate
prior to stroke

Intervention
Period
3 sessions
/week for 6
weeks.
Follow ups
assessments
at 6- and 12months postenrollment

RAGT protocol

CGT protocol

1 hr 30 minutes of RAGT with HAL® + 30
minutes of conventional gait training. 30
minutes of applying and removing device
included in RAGT time. Gait training with
HAL® performed with BWS (offload = 9 kg)
on a treadmill. Training Performed by one
physiotherapist knowledgeable in HAL®
procedures. Session 1 dedicated to
acquaintance of HAL in CAC (fully
autonomous) mode. Following sessions done
in CVC (voluntary) mode. BWS support
reduced, and treadmill speed increased as
intervention progressed, matching the
improvement needs of the subject.

1 hr 30 minutes of conventional
training with a physical therapist.
Conventional Training was done
in accordance to the current
recommended stroke outpatient
practice in Sweden. CGT
included overground walking and
treadmill usage without the use of
BWS. Physiotherapy also
included strength and balancing
exercises.

5 sessions
/week for 2week
intervention.
Subjects
could opt for
an additional
2 weeks of
intervention
(RAGT or
CGT)
4 sessions
/week over
4-week
intervention.
Follow-up
assessment
at 6 months
postenrollment

60 minutes of electromechanically assisted gait
training with ExoWalk®. Subjects also received
additional, outside occupational therapy

60 minutes of physical therapistassisted gait training with the
"conventional method" (YeonGyo et al 2020). Subjects also
received additional, outside
occupational therapy.

< 1 hr 30 minutes of gait training with HAL®.
HAL® training was conducted with BWS on a
treadmill. One or two physical therapists educated in
HAL® schematics were present. Session 1 was done
in CAC (fully autonomous) mode with BWS set at
30% of the subject's weight. Following sessions
were done in CVC (voluntary) mode and treadmill
speed was initially set at 0.5 km/hr. BWS was
reduced, and treadmill speed increased as training
progressed

30-60 minutes of conventional
training. Conventional Training
sessions were individualized and
were performed in accordance
with stroke-recovery guidelines
set by Langhorne et al. 2011.

3 sessions
/week over
4-week
intervention.
Follow-up
assessments
at 8- and 12weeks postenrollment

20 minutes of gait training with HAL®. Training
done with BWS and in the presence of two
physiotherapists knowledgeable in HAL®
procedures. One physical therapist operated the
BWS system while another supported the hip and
trunk posterior to the subject. CVC (voluntary)
mode was used unless the subjects required
additional assistance provided by CAC (fully
autonomous) mode. BWS was reduced and walking
speed and duration increased as training progressed.
Subjects also received additional, outside physical,
occupational, and speech therapy.

20 minutes of conventional gait
training with physical therapists.
Conventional gait training was
customized to match patient
tolerance. Walking intensity and
duration was gradually increased
as training progressed. Subjects
also received additional, outside
physical, occupational, and
speech therapy.
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Table 3 cont.)
Study

Subject Population Size/
Inclusion

Intervention
Period

RAGT Protocol

CGT Protocol

End-Effector-Based Studies
Kim et al
2019

Aprile et
al. 2019

•n = 58
•First-ever stroke
•>18 yoa
•Ischemic or
hemorrhagic stroke
•FAC ≥ 2
•Previously
independent walker,
hemiparesis
•n = 26
•Subacute stroke
•2 weeks – 6 months
post-stroke
•18-80 yoa
•Ability to stand
upright for 60 seconds
•Ability to walk
unassisted or with little
assistance
•No limitation of joint
movement
•Cognitive ability to
give written consent

5 sessions
/week over
3-week
intervention

3 sessions
/week for 20
total sessions

30 minutes of gait training with Morning-Walk + 1
hour of conventional physical therapy. Ground-level
cadence started at 30-35 steps/minute and was
adjusted according to patient performance. Subjects
progressed to up and down stair gait parameters.
Conventional physical therapy was “based on
traditional neurodevelopmental treatment
techniques” (Kim et al 2019). Included sitting and
standing practice and muscle strengthening.
45 minutes of gait training with G-EO System®. All
subjects started with BWS set to 30-40% of
subject’s body weight and an initial speed of 1.5
km/hr. BWS was reduced to 15% of subject body
weight and walking speed increased to 2.2-2.5
km/hr. Patients could rest but were asked to
complete a minimum of 300 steps and 5 minutes of
continuous walking per session.

1 hour 30 minutes of conventional
physical therapy. Conventional
physical therapy was “based on
traditional neurodevelopmental
treatment techniques”. (Kim et al
2019). Included sitting and
standing practice, muscle
strengthening, and gait training.

30 minutes of gait training with RoboWalk followed
by 30 minutes of on-on-one multidisciplinary,
conventional physical therapy. 80% of treatment
sessions involved training with RoboWalk.

1 hour of multidisciplinary oneon-one conventional physical
therapy.

Conventional Therapy training
time varied between each session.
Conventional therapy involved
gait training with aid devices or
strength bars, muscle
strengthening and control
exercises, stretching, and sitting
to standing practice.

Cable-Driven-Based Studies
Stolz et al
2019

•n = 36
•Subacute stroke
•<3 months post-stroke
•>18 yoa
•Ability to give willing,
informed consent
themselves or through
next-of-kin

5 sessions
/week for 18
total
sessions.
Follow-up at
4 weeks
postdischarge.

the lower limb joints (Li et al. 2021, Kang et al. 2021, Aprile et al. 2019). Patient Questionnaires
were commonly used to measure overall quality of life, such as the Stroke Impact Scale
(Palmcrantz et al. 2021), Patient Health Questionnaire (Louie et al. 2021), EuroQol 5-Dimensional
Test (Stolz et al. 2019), and a novel 10-question self-questionnaire measuring patient satisfaction
from Kang et al. 2021. Other commonly used outcome measurements amongst the 11 studies
included the Motricity Index (Kang et al. 2021, Yeon-Gyo et al. 2020, Aprile et al. 2019, Kim et
al. 2019), Barthel Index (Palmcrantz et al. 2021, Wall et al. 2020, Kim et al. 2019), Timed-Up-
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and-Go Test (Stolz et al. 2019, Aprile et al. 2019, Watanabe et al. 2017), Cadence in steps/minute
(Kang et al. 2021, Li et al. 2021, Watanabe et al 2017), Stride length in meters (Kang et al. 2021,
Li et al. 2021, Watanabe et al. 2017), and the Rivermead Mobility Index (Kang et al. 2021, Kim
et al. 2019).
Mean improvement differences for all clinical outcome measures were reported in eight
studies (Yeung et al. 2021, Kang et al. 2021, Li et a. 2021, Palmcrantz et al. 2021, Yeon-Gyo et
al. 2020, Stolz et al. 2019, Kim et al. 2019, Watanabe et al. 2017). Median values indicating
improvements in all outcome measures were reported in two studies. (Wall et al. 2020, Aprile et
al. 2019). Louie et al. 2021 reported the median improvement in FAC and the mean improvements
for all other outcome measures, including 6MWT, Gait Speed, BBS, and FMA-LE.

Post-Intervention Within-Group Differences and Clinically Important Differences

Device Type
Studies with an RAGT intervention involving an exoskeleton observed a mean weighted
FAC improvement of +1.17 (SD = 1.02) in RAGT groups and +1.08 (SD = 1.11) in CGT groups
(Louie et al. 2021, Yeung et al. 2021, Kang et al. 2021, Li et al. 2021, Yeon-Gyo et al. 2020, Wall
et al. 2020, Kim et al. 2019, Aprile et al. 2019, Watanabe et al. 2017) directly after the first
assessment. Excluding studies reporting only median values (Louie et al. 2021, Wall et al. 2020,
Aprile et al. 2019), the average improvement in FAC for exoskeleton-based studies was observed
to be +0.74 (SD = 0.52) in RAGT groups and +0.49 (SD = 0.31) in CGT groups. Exoskeletonbased studies that recorded mean improvements in 6MWT (Li et al. 2021, Palmcrantz et al. 2021,
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Yeon-Gyo et al. 2020, Watanabe et al. 2017) identified a mean improvement of +36.67 m (SD =
35.16 m) in RAGT groups and +23.41 m (SD = 14.66) in CGT groups.
Five out of the seven exoskeleton-based groups including FAC as an outcome measure saw
clinically meaningful differences in mean or median FAC improvement (FAC ≥ 1) (Louie et al.
2021, Yeung et al. 2021, Li et al. 2021, Wall et al. 2020, Watanabe et al. 2017). These groups also
observed significant within group improvements in FAC (excluding groups that did not account
for within-group differences) (p>0.05). Only two of seven CGT groups in exoskeleton-based
studies saw a clinically important difference in FAC (Louie et al. 2021, Wall et al. 2020). Three
of the CGT groups observed significant within-group differences in FAC (excluding groups that
did not account for within-group differences). Two of the four exoskeleton-based studies saw
clinically important differences in 6MWT (6MWT ≥ 20.0 m for subacute subjects, 6MWT ≥ 34.4
for chronic stroke subject), regardless of RAGT and CGT allocation (Li et al. 2021, Watanabe et
al. 2017). Palmcrantz et al. 2021 was the only study to not see significant within-group differences
in 6MWT after all assessments were done, regardless of allocation group. The CGT group saw
significant improvement in 6MWT immediately after the intervention had ended, but this
improvement significantly decreased to an insignificant improvement value at the 6-month postinitiation assessment.
Studies including an RAGT group involving an end-effector device (Kim et al. 2019,
Aprile et al. 2019) saw a mean weighted improvement in FAC of +1 (SD = 0) for RAGT groups
and +0.71 (SD = 0.13) in CGT groups. Kim et al. 2019 recorded a mean improvement in FAC of
+1 for RAGT groups and +0.8 in RAGT groups. The RAGT groups present in these studies saw
clinically important differences in mean or median FAC improvement, while CGT groups
observed no clinically important differences. The end-effector focused studies also saw significant
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within-group differences for the majority of outcome measurements accounted for, regardless of
group allocation. The Modified Ashworth Scale in the CGT group from Aprile et al. 2019 was the
only outcome measure that did not improve significantly post-intervention amongst the studies
including an end-effector device.
The single study focusing on a cable-actuated device (Stolz et al. 2019) saw a mean
improvement in 6MWT in the first assessment of +134.1 m in the RAGT group and +86.38 m in
the CGT group. Both values were considered clinically important, but within-group analysis
revealed this improvement was not considered significant.
Number of Treatment Sessions
Studies that conducted 12 or fewer treatment sessions throughout their intervention saw a
weighted mean improvement in FAC of +0.40 (SD = 0.39) in RAGT groups and +0.28 (SD = 0.20)
in CGT groups. (Kang et al. 2021, Yeon-Gyo et al. 2020, Watanabe et al. 2017). Only the RAGT
group in Watanabe et al. 2017 saw clinically important differences in FAC. Kang et al. was the
only one of these studies that saw no significant within-group differences in FAC. The mean
weighted improvement in BBS from Kang et al. 2021 and Yeon-Gyo et al. 2020 was +1.62 (SD =
1.41) for RAGT groups and +2.70 (SD = 0.70) for CGT groups. Yeon-Gyo et al. 2020 observed
significant within-groups differences in BBS in both treatment groups, but no studies conducting
fewer than 12 sessions saw clinically important improvements in BBS.
Studies that conducted greater than 12 treatment sessions saw a mean weighted
improvement in FAC of +1.57 (SD = 0.75) for RAGT groups and +1.37 (SD = 0.94) for CGT
groups (Louie et al. 2021, Yeung et al. 2021, Li et al. 2021, Palmcrantz et al. 2021, Wall et al.
2020, Stolz et al. 2019, Kim et al. 2019, Aprile et al. 2019). When excluding studies that reported
median improvement values, the mean weighted improvement in FAC was +1.12 (SD = 0.16) for
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RAGT groups and +0.81 (SD = 0.06) for CGT groups. All mean or median improvements in FAC
for RAGT groups were considered clinically important. Only the CGT groups in Louie et al. 2021
and Wall et al. 2020 reported improvements that were considered clinically important. The
remainder of these studies observed CGT groups with FAC improvements <1. Mean weighted
improvement in BBS amongst these studies was +14.74 (SD = 5.75) for RAGT groups and +11.81
(SD = 5.03) for CGT groups (Louie et al. 2021, Yeung et al. 2021, Palmcrantz et al. 2021, Wall et
al. 2020, Kim et al. 2019). When excluding median values, the improvement in BBS amongst these
studies was +14.91 (SD = 6.35) for RAGT groups and +11.27 (SD = 5.37) for CGT groups.
Palmcrantz et al. 2021 was the only study to not see significant within-group differences or
clinically important differences in BBS for either treatment group.
Stroke Type: Subacute vs Chronic
Studies that only included subacute patients or patients with an average time of duration
since stroke <6 months observed mean weighted improvements in FAC of +1.51 (SD = 0.72) for
RAGT groups and +1.28 (SD = 1.59) in CGT groups (Louie et al. 2021, Yeung et al. 2021, Li et
al. 2021, Wall et al. 2020, Kim et al. 2019, Aprile et al. 2019, Watanabe et al. 2017). When
excluding studies that reported median values, the mean weighted improvement in FAC was +1.11
(SD = 0.15) in RAGT groups and +0.76 (SD = 0.13) in CGT groups. Mean weighted improvements
in 6MWT were observed to be +119.38 m (SD = 21.2 m) in RAGT groups and +63.68 m (SD =
19.6 m) in CGT groups (Li et al. 2021, Stolz et al. 2019, Kim et al. 2019, Aprile et al. 2019).
Excluding Aprile et al. 2019, these mean weighted improvements in 6MWT were found to be
+113.67 m (SD = 22.46 m) for RAGT groups and +64.9 m (SD = 22.54 m) for CGT groups. Mean
weighted improvements in 10mWS for subacute studies were +1.14 m/s (SD = 0.78 m/s) for RAGT
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groups and +0.31 m/s (SD = 0.09 m/s) in CGT groups (Yeung et al. 2021, Stolz et al. 2019, Kim
et al. 2019).
All RAGT groups amongst these studies observed clinically important differences in
improvement for FAC. All subacute subject studies that conducted a test of significance on withingroup differences saw significant improvements in FAC in all RAGT and CGT groups. Only the
CGT groups in studies that reported median values observed clinically important differences. The
remainder of these studies observed CGT groups with FAC improvements <1.
All the subacute subject studies that measured 6MWT and 10mWS found clinically
important differences in these categories in both RAGT and CGT groups. Stolz et al. 2019 did not
perceive a significant improvement in 6MWT and 10mWS in both RAGT and CGT groups. The
CGT group in Aprile et al. 2019 did not report a median improvement in 10mWS that was
considered significant. The remainder of these groups reported significant within-group
differences for 6MWT and 10mWS.
Studies only including chronic stroke subjects as part of their inclusion criteria observed a
mean weighted improvement in FAC of +0.18 (SD = 0.17) in RGAT groups and +0.20 (SD = 0.18)
in CGT groups at discharge (Kang et al. 2021, Yeon-Gyo et al. 2020). Mean weighted
improvements in 6MWT were +15.9 m (SD = 7.31 m) for RAGT groups and +21.24 m (SD =
0.39) for CGT groups at discharge (Palmcrantz et al. 2021, Yeon-Gyo et al. 2021). Mean weighted
changes in 10mWS were +0.01 m/s (SD = 0.11 m/s) in RAGT groups and -0.15 m/s (SD = 0.30
m/s) for CGT groups at discharge (Palmcrantz et al. 2021, Kang et al. 2021, Yeon-Gyo et al. 2020).
The studies that only included chronic stroke subjects did not observe any clinically important
differences in FAC, 6MWT, 10mWS, or BBS in either RAGT or CGT groups. Yeon-Gyo et al.
2020 was the only chronic stroke study to see significant within-group improvements in FAC,
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10mWS, 6MWT, and BBS in both allocation groups. The CGT group in Palmcrantz et al. 2021
saw significant within-group improvement in 6MWT and BBS at the post-intervention assessment.
As stated previously, the significant improvement in 6MWT was subsequently lost by the time of
the 6-month and 12-month assessments. The only outcome improvement in Kang et al. 2021 found
to be clinically important and significant was the MAS-LL in both groups. The CGT group in
Kang et al. 2021 also saw significant improvement in BBS. Baseline Walking Ability
Studies that only included subjects with an FAC between 0-1 saw median improvements
in FAC at post-intervention ≥ 2 for RAGT groups (Weighted Mean = +2.54, SD = 0.51) and CGT
groups (Weighted Mean = +2.76, SD = 0.25) immediately after intervention (Louie et al. 2021,
Wall et al. 2020). Groups that included subjects that had a mean baseline FAC > 1 or included
subjects that could at least ambulate with assistance observed a mean average improvement in
FAC of +0.83 (SD = 0.44) for RAGT groups and +0.03 (SD = 0.62) for CGT groups. Excluding
Aprile et al., these improvements in FAC were observed to be +0.81 (SD = 0.46) for RAGT groups
and +0.03 (SD = 0.63) for CGT groups. Study populations included in each subgroup allocation
are summarized in Table 4.

Follow-Up Assessments
Studies that included at least one follow-up assessment (Louie et al. 2021, Palmcrantz et
al. 2021, Wall et al. 2020, Stolz et al. 2019, Watanabe et al. 2017) continued to see improvements
in the majority of outcome measures after the initial assessment. The CGT group in Palmcrantz et
al. was the only group amongst all studies to see a significant decrease in any outcome measure
(6MWT) at the 2nd and 3rd assessment. The RAGT group in Palmcrantz et al. continued to improve
in 6MWT at the2nd and 3rd assessment, but this improvement was not considered significant or
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clinically important. The CGT group in Watanabe et al. 2017 experienced a decrease in FAC from
T1 – T2 and a decrease in 6MWT from T2 – T3. The RAGT group in Watanabe et al. also saw a
decrease in FMA-LE from T0-T2 and T3 and a decrease in 6MWT from T1 to T2. The significance
of these decreases in outcome measure were not indicated in the study. Watanabe et al. also saw a
decrease in FMA-LE from T0-T2 and T3 and a decrease in 6MWT from T1 to T2. The significance
of these decreases in outcome measure were not indicated in the study.

Table 4) Mean weighted improvements in commonly shared outcome measures from baseline to post-intervention
based on various individual study/subject characteristics. Subgroups are based on inclusion criteria from individual
studies. Population sizes are based on the total number of subjects within each study including the given subgroup
characteristic in their inclusion criteria. “ * ” indicates the inclusion of subjects from studies only presenting
median values for subjects (Loui et al. 2021e, Wall et al. 2020, Aprile et al. 2019). No “ * ” indicates the exclusion
of median values.
Variable
Robotic Device
Type

Subgroup

Studies matching Subgroup

RAGT Weighted Mean (Population Size)

Exoskeleton

Louie et al. 2021, Yeung et al. 2021, Kang
et al. 2021, Li et al. 2021, Palmcrantz et
al. 2021, Yeon-Gyo et al. 2020, Wall et al.
2020, Watanabe et al. 2017
Kim et al. 2019, Aprile et al. 2019

FAC = +0.74 (76), *FAC = +1.17 (111)

<12 sessions

Kang et al. 2021, Yeon-Gyo 2020,
Watanabe et al. 2017

>12 sessions

Louie et al. 2021, Yeung et al. 2021, Li et
al. 2021, Palmcrantz et al. 2021, Wall et
al. 2020, Stolz et al. 2019, Kim et al.
2019, Aprile et al. 2019
Louie et al. 2021, Yeung et al. 2021, Li et
al. 2021, Wall et al. 2020, Stolz et al.
2019, Kim et al. 2019, Aprile et al. 2019,
Watanabe et al. 2017

FAC = +0.40 (45)
BBS = +1.62 (33)
FAC = +1.12 (59), *FAC = +1.57 (108)
BBS = +14.91 (74), *BBS = +14.74 (90)

End-Effector
Number of
Treatment Sessions

Stroke Recovery
Phase

Baseline Walking
Ability

Subacute

Chronic

Kang et al. 2021, Palmcrantz et al. 2021,
Yeon-Gyo et al. 2020

FAC ≤ 1

Louie et al. 2021, Wall et al. 2021

FAC ≥ 1

Yeung et al. 2021, Kang et al. 2021, Li et
al. 2021, Palmcrantz et al. 2021, YeonGyo et al. 2020, Stolz et al. 2019, Kim et
al. 2019, Aprile et al. 2019, Watanabe et
al. 2017

FAC = +1 (28), *FAC = +1 (42)

FAC = +1.11 (71), *FAC = +1.28 (120)
6MWT = +113.67 m (49), *6MWT = +119.38 m (63)
10mWS = +1.14 m/s (62)
FAC = +0.18 (33)
6MWT = +15.9 m (31)
10mWS = +0.01 m/s (46)
*FAC = +2.54 (35)
FAC = +0.81 (104), *FAC = +0.83 (118)
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Post-intervention Between-Group Differences

RAGT v CGT
Of the nine studies that included FAC as an outcome measure, five of the studies found
that RAGT improved in FAC greater than CGT (Yeung et al. 2021, Li et al. 2021, Kim et al. 2019,
Aprile et al. 2019, Watanabe et al. 2017). Louie et al. 2021 and Kang et al. 2021 observed no
difference in FAC improvement between RAGT and CGT groups. Excluding median values, the
weighted mean of FAC across all RAGT groups was +0.81 (SD = 0.46), while the weighted mean
for FAC in CGT groups was +0.58 (SD = 0.30). This trend of greater improvement in FAC for
RAGT groups held true when including median values (Louie et al. 2021, Wall et al. 2020, Aprile
et al. 2019).
Across the six studies that included a difference in baseline and post-intervention 6MWT
values, five found greater improvement in RAGT groups than CGT directly after intervention (Li
et al. 2021, Yeon-Gyo et al. 2020, Stolz et al. 2019, Aprile et al. 2019, Watanabe et al. 2017). The
weighted mean of 6MWT for all RAGT groups was +63.09 m (SD = 45.8 m), while CGT groups
observed an overall weighted mean of +38.07 m (SD = 22.92 m). This pattern of greater overall
improvement in 6MWT for RAGT groups held true when including median values (Aprile et al.
2019).
All six studies that included a baseline and post-intervention difference in 10mWS found
a greater in improvement in RAGT groups than CGT groups (Yeung et al. 2021, Kang et al. 2021,
Palmcrantz et al. 2021, Yeon-Gyo et al. 2020, Stolz et al. 2019, Kim et al 2019). Although both
groups in Kang et al. 2021 observed decreases in 10mWS post-intervention, the RAGT group
produced a less negative value in 10mWS. The mean weighted average for RAGT groups in
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10mWS was +0.65 m/s (SD = 0.82 m/s), while CGT groups had a mean weighted 10mWS
improvement of +0.11 m/s (SD = 0.31 m/s).
Of the seven studies that observed BBS as an outcome measure, four studies found greater
improvement in BBS in RAGT groups than CGT groups (Louie et al. 2021, Yeung et al. 2021,
Yeon-Gyo et al. 2020, Kim et al. 2019). Excluding median values, the weighted mean
improvement of BBS for RAGT groups was +10.81 (SD = 8.15), while CGT observed an overall
weighted mean improvement of +8.64 (SD = 5.98). This pattern of greater improvement in BBS
holds true when including median values (Aprile et al. 2019). Of the 5 studies that included FMALE as an outcome measure, 3 studies found greater improvement in CGT groups than RAGT
groups (Palmcrantz et al. 2021, Wall et al. 2020, Watanabe et al. 2017). Excluding median values,
overall weighted mean improvement in FMA-LE was greater in RAGT groups than CGT groups.
Weighted mean improvement in FMA-LE in RAGT groups was +3.69 (SD = 2.48), while CGT
groups observed an overall mean weighted improvement of +2.34 (SD = 0.76). This pattern of
greater improvement in FMA-LE in RAGT groups holds true when including median values (Wall
et al. 2020).
Of the 3 studies that observed MAS-LL as an outcome measure, 2 studies found RAGT
groups decreased in muscle spasticity of the lower limbs more so than CGT groups (Kang et al.
2021, Aprile et al 2019). Excluding median values, RAGT groups observed a mean weighted
decrease in MAS-LL of -0.49 (SD = 0.58) and CGT groups saw a decrease of -0.47 (SD = 0.34).
This pattern of decreased spasticity in RAGT groups holds true when including median values
(Aprile et al. 2019). Studies including each outcome measure are listed in Table 5.
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Table 5) Mean Weighted improvements of all RAGT and CGT subjects from studies including outcome measures
listed in Table 1. Population sizes are based on the total number of subjects across all studies including a given
outcome measure. “ * ” indicates a weighted mean includes subjects from studies only presenting median values
for subjects (Loui et al. 2021, Wall et al. 2020, Aprile et al. 2019). No “ * ” indicates the exclusion of median
improvement values.

Outcome
Measure
FAC

6MWT
10MWT
BBS
FMA-LE
MAS-LL

Studies including
Outcome Measure
Louie et al. 2021, Yeung et al. 2021,
Kang et al. 2021, Li et al. 2021,
Yeon-Gyo et al. 2020, Wall et al. 2020,
Kim et al. 2019, Aprile et al. 2019,
Watanabe et al. 2017
Li et al. 2021, Palmcrantz et al. 2021,
Yeon-Gyo et al. 2020, Stolz et al. 2019,
Aprile et al. 2019, Watanabe et al. 2017
Yeung et al. 2021, Kang et al. 2021,
Palmcrantz et al. 2021,
Yeon-Gyo et al. 2020, Stolz et al. 2019,
Kim et al. 2019
Louie et al. 2021, Yeung et al. 2021,
Kang et al. 2021, Palmcrantz et al. 2021,
Yeon-Gyo et al. 2021, Wall et al. 2020,
Kim et al. 2019
Louie et al. 2021, Li et al. 2021,
Palmcrantz et al. 2021, Wall et al. 2020,
Watanabe et al. 2017
Kang et al. 2021, Li et al. 2021,
Aprile et al. 2019

RAGT Weighted Mean
Improvement
(Population Size)

CGT Weighted Mean
Improvement
(Population Size)

+0.81 (104)
*+1.22 (153)

+0.58 (109)
*+1.04 (104)

+63.08 m (74)
*+75.78 m (90)
+0.66 m/s (108)

+38.07 m (74)
*+42.05 m (90)
+0.11 m/s (113)

+10.81 (107)
*+11.22 (123)

+8.64 (114)
*+9.36 (130)

+3.69 (61)
*+4.27 (77)
-0.49 (32)
*-0.50 (48)

+2.35 (59)
*+3.34 (75)
-0.47 (30)
*-0.30 (46)

Individual Study Outcome Significance
The majority of individual outcome measures observed amongst all 11 studies perceived
no significant differences between RAGT and CGT. 5 studies did not observe any significant
difference in any outcome measurement accounted for in this article (Louie et al. 2021, Yeon-Gyo
et al. 2020, Wall et al. 2020, Stolz et al. 2019, Aprile et al. 2019).
Watanabe et al. was the only study to observe a significant difference in improvement of
FAC. RAGT had significantly improved in FAC by the end of intervention and at follow-up
assessments (p = 0.02). This p-value was found using an interaction effects model. All other
outcome improvements from Watanabe et al. 2017 were not found to be significantly different.
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Li et al. was the only study to see a significant difference in either 6MWT or Fugl-Meyer
Assessment of the Lower Extremities. Subjects who had undergone RAGT had significantly
improved in the 6MWT (p = 0.022) and FMA-LE (p = 0.044) over CGT. All other outcome
measures were not found to be significantly different.
Yeung et al. 2021 was the only study to indicate any significant difference between groups
for any test measuring gait speed (10mWS). RAGT had been found to significantly improve
subject’s maximum gait speed over CGT. However, the p value determined by the Mann Whitney
U Test was not specified in the article. All other between-group comparisons in outcome
measurement were not found to be significant
Kang et al. 2021 and Kim et al. 2019 both observed significant differences in improvement
in BBS between RAGT and CGT groups. CGT had been found to significantly improve BBS over
RAGT in Kang et al. (p = 0.004). However, RAGT had been found to significantly improve BBS
over CGT in Kim et al. (p = 0.047). Both studies observed no other significantly between-group
differences.
Palmcrantz et al. 2021 was the only study to measure total distance walked in meters by
subjects undergoing either RAGT or CGT. RAGT had allowed stroke subjects to walk a
significantly longer total distance on treadmill than CGT subjects (p = 0.002).
No individual studies observed significant between-group differences in MAS-LL. Details
on outcome measures and significant differences from individual studies are outlined in Table 6.
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Table 6) Mean and median improvements in outcome measures from individual clinical trials. Significant between
group differences within each trial are listed. “T0” indicates baseline assessments. “T1” indicates values
measured immediately post-intervention, while “T2” and “T3” represent follow up assessments. “•” indicates an
individual outcome is presented as a median improvement or a study presented median improvements in outcome
measurement. All other values are mean improvements. Bold values indicate an outcome measure met the minimum
clinically important difference presented in Table 1. “*” means a study demonstrated a significant within-group
improvement (p < 0.05) for a given outcome measure. “**” indicates a study demonstrated a given outcome
measure significantly decreased from post-intervention to follow-up assessment. “‡” indicates that a study did not
conduct a statistical test on within-group differences. “†” indicates a value was only taken post-intervention,
meaning the measurement presented is face-value rather than an improvement difference.
RAGT Group
‡Louie et al.
2021
(Subacute)

Yeung et al.
2021
(Subacute)
Kang et al.
2021
(Chronic)
Li et al.
2021
(Subacute)

Palmcrantz et al.
2021
(Chronic)

CGT Group

(T1-T0):
FAC = +3•
6MWT = +117 m†
FMA-LE = +5.7
BBS = +21.3
Gait Speed = +0.38 m/s†
(T2-T0):
FAC = +4•
6MWT = +164.5 m†
FMA-LE = +6.2
BBS = +22.5
Gait Speed = 0.52†
(T1-T0):
FAC = +1.4*
BBS = +18.8*
10mWS = +0.32 m/s*
(T1-T0):
FAC = 0
BBS = +0.1
10mWS = -0.15 m/s
MAS-LL = -1.1*
(T1-T0):
FAC = +1.11*
6MWT = +89.36 m*
FMA-LE = +5.77*
MAS-LL = +0.04

(T1-T0):
FAC = +3•
6MWT = +91 m†
FMA-LE = +3.3
BBS = +18.6
Gait Speed = +0.35 m/s†
(T2-T0):
FAC = +4•
6MWT = 117 m†
FMA-LE = +4.5
BBS = +23.8
Gait Speed = 0.42 m/s†
(T1-T0):
FAC = +0.9*
BBS = +14.4*
10mWS = +0.17 m/s*
(T1-T0):
FAC = 0
BBS = +3.5*
10mWS (SSV) = -0.6 m/s
MAS-LL = -0.8*
(T1-T0):
FAC = +0.74*
6MWT = +42 m*
FMA-LE = +2.66
MAS-LL = -0.13

(T1-T0):
6MWT = +7.53 m
10mWS = +0.127 m/s
BBS = +2.69
FMA-LE = +0.44
Completed Walking Distance =
15420.13 m
(T2-T0):
6MWT = (Value not Specified)
(T3-T0):
6MWT = (Value not Specified)

(T1-T0):
6MWT = +21.69 m*
10mWS = +0.05 m/s
BBS = +2.77*
FMA-LE = +1.71
Completed Walking Distance =
6323.29 m
(T2-T0):
6MWT = +6.31 m**
(T3-T0):
6MWT = +2.16 m

Between-Group
Differences
(p < 0.05)
None

10mWS:
RAGT > CGT
(p = not specified)
BBS:
CGT > RAGT
(p = 0.004)
6MWT:
RAGT > CGT
(p = 0.022)
FMA-LE:
RAGT > CGT
(p = 0.044)
Completed Walking
Distance:
RAGT > CGT
(p = 0.002)
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Table 6 cont.)
RAGT
Yeon-Gyo et al.
2020
(Chronic)
•‡Wall et al.
2020
(Subacute)

‡Watanabe et al.
2017
(Subacute)

Kim et al.
2019
(Subacute)
•Aprile et al.
2019
(Subacute)
Stolz et al.
2019
(Subacute)

(T1-T0) 10-sessions:
FAC = +0.33*
6MWT = +22.11 m*
10mWS = +0.05 m/s*
BBS = +2.89*
(T1-T0):
FAC = +2
2MWT = +14.75 m
BBS = +14
FMA-LE = +6.5
(T2-T0):
FAC = +4
2MWT = +35.75 m
BBS = +37
FMA-LE = +13.5
(T1-T0):
FAC = +1
6MWT = +64.3 m
FMA-LE = +1.1
(T2-T0):
FAC = +1.5
6MWT = +61.9 m
FMA-LE = -0.8
(T3-T0):
FAC = +1.6
6MWT = +74.3
FMA-LE = -0.8
(T1-T0):
FAC = +1*
10mWS = +2 m/s*
BBS = +14.3*
(T1-T0):
FAC = +1*
6MWT = +134.5 m*
MAS-LL = -0.5*
(T1-T0):
6MWT = +134.1 m
10mWS = +0.52 m/s
(T2-T0):
6MWT = +152.56 m
10mWS = +0.58 m/s

CGT
(T1-T0) 10 sessions:
FAC = +0.35*
6MWT = +20.91 m*
10mWS = +0.04 m/s*
BBS = +2.10*
(T1-T0):
FAC = +2.5
2MWT = +12.5 m
BBS = +14.5
FMA-LE = +7
(T2-T0):
FAC = +4
2MWT = +68.5 m
BBS = +37.5
FMA-LE = +8
(T1-T0):
FAC = +0.5
6MWT = +33.9 m
FMA-LE = +1.4
(T2-T0):
FAC = +0.4
6MWT = +35.8
FMA-LE = +1.6
(T3-T0):
FAC = +0.7
6MWT = +24.1
FMA-LE = +2
(T1-T0):
FAC = +0.8*
10mWS = +0.4 m/s*
BBS = +9.6*
(T1-T0):
FAC = +0.5*
6MWT = +60.5 m
MAS-LL = 0
(T1-T0):
6MWT = +86.38 m
10mWS = +0.28 m/s
(T2-T0):
6MWT = +88.91 m
10mWS = +0.26 m/s

Between-Group
Differences
(p < 0.05)
None

None

FAC at 4, 8, and 12
weeks:
RAGT > CGT
(p = 0.02)

BBS:
RAGT > CGT
(p = 0.047)
None

None

Subject Quality of Life Questionnaires
The improvements in self-questionnaire scores delivered in Louie et al. 2021 (Patient
Health Questionnaire 9), Kang et al. 2021 (novel 10-question self-questionnaire), Palmcrantz et
al. 2021 (Stroke Impact Scale) were all found to be greater in the RAGT group relative to the CGT
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group. The EuroQol-5D-5L questionnaire given in Stolz et al. 2019 found greater improvement in
overall score in the CGT group compared the RAGT group. None of the studies found significant
differences in overall questionnaire score improvements between RAGT and CGT groups.
However, Stolz et al. 2019 reported a significantly lower score for the “pain/discomfort” portion
of the EuroQol-5D-5L questionnaire in the RAGT group.

Discussion

The overarching purpose of this scoping review was to provide a detailed summary of the
literature on randomized, clinical trials for robotic-assisted gait training interventions relative to
more conventional gait training methods. As demonstrated by the screening process for this study,
there have been a limited number of studies on this subject which have been published within the
last five years.
The weighted means taken of the six outcome measures observed in this study were all
higher in RAGT groups than CGT groups. This may suggest that RAGT interventions may be
more beneficial to stroke patients in general than conventional gait training methods. This finding
is in accordance with previous meta-analyses done on the effect of RAGT on stroke patients
(Mehrholz et al. 2017, Nam et al. 2017). Most individual studies found no significant difference
in any outcome measure between RAGT and CGT groups. None of the clinical trials in this study
could specifically advocate for the use of RAGT over CGT, which is more consistent with findings
from meta-analyses by Tedla et al. 2019 and Kim 2019. These conflicting findings suggest that a
full meta-analysis on these studies should be performed to attain a better grasp on the full effect of
RAGT in stroke patients relative to CGT.
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Studies with RAGT groups including either an exoskeleton or end-effector device saw
similar improvement in FAC. Regardless of device, RAGT groups tended to see a clinically
important improvement in FAC (≥1). This is contrary to previous reviews, which have suggested
that end-effector robots tend to be more beneficial for gait recovery in stroke patients (Calabro et
al. 2021, Schroder et al. 2019, Mehrholz et al. 2017). With only 18% of studies identified in this
screening being conducted with end-effector-devices, there is major discrepancy between the
number of exoskeleton-based studies relative to the number end-effector-based clinical trials. This
discrepancy may lower the statistical power of the weighted mean included in this study. Future
clinical trials focusing on gait recovery should include more RAGT intervention groups with the
use of an end effector device.
Previous meta-analyses finding how RAGT is more beneficial for gait recovery in stroke
subjects say the assistance delivered by exoskeletons and end-effectors may allow for greater
repetition and intensity in training early-on (Mouchebouef et al. 2020, Schroder et al. 2019, Tedla
et al. 2019). This may be especially important when considering the initial ambulatory ability of a
given subject, who may benefit from the automatic assistance and BWS provided by robotic gait
trainers.
The weighted means on differences in non-ambulatory/ambulatory subject inclusion found
that studies only including non-ambulatory subjects observed greater improvements in FAC than
studies that included ambulatory subjects. Previous meta-analyses identified similar findings on
the benefits of RAGT for non-ambulatory stroke subjects (Calabro et al. 2021, Bruni et al. 2018,
Mehrholz et al. 2017, Ada et al. 2016). Gait recovery therapy for RAGT with exoskeletons endeffectors provide the assistance and BWS necessary to walk upright with normal gait cycling at
the beginning of physiotherapy. This allows non-ambulatory subjects to undergo more repetition
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and cover longer walking distances than patients partaking in conventional, manual physiotherapy
(Mouchebouef et al. 2020, Ada et al. 2016). This finding may also be confounded by the maximum
score of the FAC measurement. Since subjects can only have a maximum score of 6, subjects with
lower baseline FAC scores may have more room for ambulatory improvement.
The imbalance in RAGT devices used in clinical trials was even greater for cable-driven
devices, with only one study (9%) including such a device. Despite Stolz et al. showing clinically
important differences in 6MWT and 10mWS, very few studies have followed up on the potential
for cable-driven devices for gait recovery in stroke patients. Previous reviews barely touch on the
idea of cable-driven devices for stroke recovery. Cable-driven devices may not provide the same
type of BWS delivered by exoskeletons and end-effectors, making them especially difficult for use
by non-ambulatory patients. However, cable-driven devices may eliminate fixed-trajectory motion
caused by some exoskeletons (Wu et al. 2011), which has been known to limit recovery of gait
cycling for paretic subjects (Veneman et al. 2008). More clinical trials should be done on the
effectiveness of cable-actuated devices for gait recovery in stroke patients.
Studies that conducted greater than 12 sessions of intervention therapy observed greater
improvements in FAC and BBS than studies that conducted 12 or fewer sessions, regardless of
group allocation. The amount of time spent practicing repetitive, task specific training has been
previously correlated with improvements in walking ability (Mouchebouef et al. 2020, Tedla et al.
2019, Langhorne et al. 2011). However, Palmcrantz et al. found that greater total distance walked
did not necessarily correlate with greater improvements in functional outcome measures between
RAGT and CGT subjects. This may be due to the inclusion of only chronic stroke subjects in their
study as potential confounding factor
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Studies that observed subacute stroke subjects identified greater improvements in FAC
than studies only including chronic stroke subjects in both RAGT and CGT groups. All RAGT
groups included in a subacute stroke study saw minimal clinically important differences in FAC,
while only 2 CGT groups from subacute studies observed a minimal clinically important
improvement in FAC. This may indicate that RAGT is more beneficial to subacute stroke patients
than CGT at recovering general ambulatory ability and independence. This trend is consistent with
previous meta-analyses that have found RAGT to be clinically beneficial for subacute stroke
patients while having little to no benefit for chronic stroke subjects (Bruni et al. 2018, Mehrholz
et al. 2017, Nam et al. 2017, Kim 2019). Morone et al. 2017 even suggests that CGT may be more
beneficial to chronic stroke patients than RAGT with an exoskeleton or end-effector robot. A
review by Bruni et al. 2018 states RAGT is most beneficial the more recently a subject has suffered
from a stroke. This is further supported by previous research stating the majority of motor function
in stroke subjects with paresis is recovered within 6 weeks of stroke episode (Jorgensen et al.
1995). A review by Baronchelli et al. 2021 suggests RAGT has an optimal window for
improvement for subjects who suffered from a stroke 3 – 6 months prior, especially because
spontaneous recovery is difficult to administer for acute stroke subjects (Wall et al. 2015). Future
clinical trials should focus on what timeframe in subacute stroke recovery benefits most from
RAGT administration.
The overlap of inclusion characteristics between studies may have confounded certain
assumptions and results from this study. For example, the lesser weighted mean improvements and
less frequent minimal clinically important differences in outcome measures in chronic stroke
studies may have been confounded by their shorter average intervention lengths. This should be
seen as a limitation to the conclusions mentioned in this study. Future reviews on this subject
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should continue to determine which subject and study characteristics may play the most important
role in predicting functional outcome.
The few studies that delivered patient questionnaires tended to see greater improvements
in quality of life in RAGT groups. However, the lack of significance for improvement between
groups may indicate that subject satisfaction may be similar between RAGT and CGT. Future
studies should continue measuring self-perceived measures of improvement, because patient
motivation and satisfaction contribute greatly to gait recovery for stroke patients (Langhorne et al.
2011).
Follow-up assessments indicated that RAGT may lead to sustained and potentially
continued improvement in functional outcome measurements. Palmcrantz et al. 2021 was the only
study with a follow-up assessment to not see improvement that was considered clinically important
in their RAGT group. This may be influenced by other confounding factors, such as subject
characteristics and/or intervention protocol. All other RAGT groups maintained a clinically
important improvement in FAC at follow-up assessments. Since few studies have conducted
follow-ups on patients post-intervention, future clinical trials should continue implementing longterm assessments of RAGT to reinforce these findings.
The observed studies included significantly more males in their studies than females. This
may be due to the low age range for most of these studies. Male subjects tend to suffer from a
stroke at an earlier age than female subjects (Foerch et al. 2010). The age at which most males
tend to suffer from stroke is better reflected in clinical studies on RAGT than the age which most
females suffer from a stroke.
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The observed studies also included significantly more ischemic stroke subjects than
hemorrhagic stroke subjects. This may be due to the greater frequency of ischemic strokes than
hemorrhagic strokes in the general population (Ahangar et al. 2018).

The Current State of RAGT Clinical Trial Research
It is tough to pinpoint exactly where robotic-assisted gait therapy fits into a clinical setting.
All the studies included were randomized controlled trials. Some studies are still in the pilot phase
of developing RAGT interventions for gait recovery, such as Kang et al. 2021 and Yeon-Gyo et
al. 2020. For these studies, significantly more clinical research is needed to indicate that their
robotic gait trainers are feasible for stroke subjects in a clinical setting. Studies such as Li et al.
2021 and Kim et al. 2019 have demonstrated that the device used for their intervention is feasible
in a clinical setting and may be even more beneficial for subacute stroke patients than CGT. These
types of studies should focus on reinforcing their findings and developing more complex
interventions and analyzing the long-term effects of their interventions in future studies. Studies
such as Louie et al. 2021, Yeung et al. 2021, and Palmcrantz et al. 2021 have the necessary
literature supporting their device as a feasible option for stroke patients in a clinical setting. As a
result, these studies were able to focus their clinical trials on developing a proper intervention
strategy for gait recovery in stroke subjects and addressing research points identified in previous
review articles. Some of the most common recommendations by previous review articles that are
being addressed by clinical trials on RAGT include:

• Blinding of assessors and researchers to treatment allocation and assessments (Tedla et al.,
2019, Molteni et al. 2018, Bruni et al. 2018, Mehrholz et al. 2017)
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• Greater variability and task-specific protocols such as sitting, standing, and stair ambulation
with robotic devices. (Mouchebouef et al. 2020, Tedla et al. 2019)
• Studying the effect of RAGT on non-ambulatory stroke subjects (Calabro et al. 2021, Bruni et
al. 2018, Louie et al. 2016)
• Reducing body weight support and robotic assistance for subjects as interventions progress
(Calabro et al. 2021, Tedla et al. 2019)
• Matching session frequency and length between RAGT and CGT groups (Bruni et al. 2018,
Mehrholz et al. 2017)
• Observing quality of life differences in subjects undergoing RAGT vs CGT (Nam et al. 2017,
Wall et al. 2015)
• Studying the effect of RAGT on early-phase stroke subjects (Mehrholz et al. 2017)
• Measuring long-term effects of RAGT observed through follow-up assessments (Mehrholz et
al. 2017)

The incorporation of these research points demonstrates that the clinical field of RAGT is in
the process of eliminating research bias and building evidence based RAGT intervention protocols
for stroke patients. Although interventions for robotic gait trainers are still in development,
research on RAGT for gait recovery in stroke patients is pushing the field in a direction that is
focused, feasible, and perhaps even beneficial in a clinical setting.

Future directions for Clinical research on RAGT interventions
When looking solely at improvements in functional outcome measures, RAGT seems to be
generally more effective than CGT in recovering gait and lower limb muscle movement in stroke
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patients. This study, as well as reviews and meta-analyses published within the last five years,
suggest that RAGT may be most beneficial for stroke subjects who are non-ambulatory or in the
subacute/acute phase of stroke recovery. There are still a number of factors that need to be
addressed by future clinical trials and meta-analyses when considering the effect of RAGT on
stroke subjects.
This review identified a wide array of novel and commercially available robotic gait trainers.
In total, nine different devices were identified, all of which were directly compared to conventional
physiotherapy in a clinical trial. There is still a wide array of gait trainers that have not been
compared to conventional therapy in a clinical trial within the last five years, such as the H2®
(Bortole et al. 2015), MAK exoskeleton (Puyuelo-Quintana et al. 2020), and ReWalk® Soft
Exosuit (Awad et al. 2020). No clinical trials have been identified on the benefits of exoskeletons
vs end-effector devices. No studies have been identified that compare the direct effects of different
commercially available devices. Studies suggest that the lack of rigidity in end-effector devices
may be more task-demanding during RAGT, allowing for greater potential of lower-limb recovery
(Morone et al 2017). However, exoskeletons may allow for more assistance and greater repetition
in gait cycling for subjects with severe disabilities (Morone et al. 2017). Future studies may
consider observing session and dosage matched effects of different types of devices. Comparisons
in types of robotic gait trainers can range from broad to more specified, and may include treatments
such as:

•

Exoskeletons vs. End-effector devices

•

Static vs. Overground Exoskeletons

•

Unilateral vs. Bilateral Lower-Limb Assistance/Devices
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•

Comparing devices with voluntary vs. automatic initiation of movement

•

Comparing the impact of well-studied and/or FDA-approved robotic gait trainers on gait
recovery

Identifying improvement mechanisms of individual robotic gait trainers may also be beneficial to
determining when a certain type of device should be used. The meta-analysis by Baronchelli et al.
2021 provides an example of this concept. The Lokomat® has been shown to improve balance
more so than CGT, despite improving all other ambulatory outcome measures similarly to CGT
(Baronchelli et al. 2021). This may indicate that the Lokomat® should be used in cases of subjects
with poor trunk control and balance issues. Studies may even consider being more general in their
approach of determining when to use a certain device, such figuring out when to appropriately use
an end-effector or an exoskeleton. Calabro et al. 2021 suggests developing a standardized outcome
measure to determine the effect of RAGT on functional outcomes. This may allow for more direct
comparisons between studies by decreasing heterogeneity. However, this may undermine
mechanisms by which robotic gait trainers improve walking ability. Determining the mechanisms
by which robotic gait trainers improve certain functional outcomes measures may aid in the
development of personalized RAGT interventions for individual stroke patients.
Most clinical studies and meta-analyses found that subacute and non-ambulatory stroke
subjects benefit most from RAGT. Research on these stroke subgroups should focus on
determining proper dosage and appropriate RAGT intervention to maximize functional
improvement. There is still room for research on which demographics of stroke patients may
benefit most from RAGT. No clinical trials were identified that compared the effects of RAGT on
ambulatory and non-ambulatory chronic stroke subjects. Future RAGT trials should allocate
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treatment in chronic stroke subjects based on FAC or ambulatory ability. Wall et al. 2020 also
identified age as a potential predicting factor in ambulatory improvement, with younger stroke
subjects seeing greater ambulatory improvement than older subjects. A previous study by Kwah
et al. 2013 demonstrated how age may be potential predictor for recovery of ambulation in stroke
patients. Future studies may consider allocating subgroups based on age ranges to determine its
predicting effect of RAGT on gait recovery.
There are still factors within the clinical field of RAGT that have seldom been addressed.
Many previous reviews have called on researchers to observe the economic effects of RAGT, such
as the impact on personnel and device maintenance costs (Kim 2019, Mehrholz et al. 2017, Wall
et al. 2015, Meyer-Heim et al. 2013). This is an important area of research that may further
determine if the benefits of RAGT outweigh the costs of performing this kind of physiotherapy for
stroke patients. Only one study was identified that explored the cost-effectiveness of RAGT, which
found that RAGT may provide savings over CGT for gait recovery patients with spinal cord
injuries (Pinto et al. 2020). Future clinical trials should focus on comparing the cost-effectiveness
of RAGT to CGT for stroke patients.
For well-studied robotic gait training devices, clinical research should focus on fine-tuning
intervention dosage of RAGT. Studies such as Louie et al. 2021 and Yeung et al. 2021 have
identified previously published research on intervention dosage and frequency. However, YeonGyo et al. 2020 was the only identified study to observe the effect of RAGT for 2 weeks (10
sessions) vs 4 weeks (20 sessions). Participants in the 4-week RAGT group experienced greater
overall improvement in functional outcome measurements than the 2-week RAGT group (YeonGyo et al. 2020). Mouchebouef et al. 2020 recommends undergoing a minimum of 1200 minutes
of RAGT per session for the intervention to be effective. Future studies may also want to consider
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intervention lengths, session lengths, and session frequency as potential variables for subgroup
allocation in RAGT clinical trials. Previous reviews have found that RAGT done in tandem with
CGT is more beneficial than CGT alone for hemiparetic stroke patients, indicating that RAGT may
be more beneficial as a support tool for CGT (Mehrholz et al. 2017, Morone et al. 2017). Future
clinical trials should compare the dosage-matched effects of RAGT + CGT to RAGT alone in
hemiparetic stroke populations.
There were several limitations to the studies included in this review that may decrease their
validity. The most common limitation was the small sample sizes of allocation groups. All the
studies included in this review cited limited sample sizes as a confounding variable, which may
decrease the internal validity of the findings in these clinical trials. Future studies may consider
having a minimum of 50 patients per group allocation to increase the internal validity of findings
(Mouchebouef et al. 2020). Most of the studies only included stroke subjects from one or two
rehab centers, meaning the samples may not be representative of the general stroke population.
Heterogeneity of subject characteristics and group allocation were high across all the studies
included. Subjects of focus were typically either chronic or subacute in stroke recovery phase.
However, factors such as age, initial walking ability, and stroke type were variable amongst the
subjects in individual studies. At least 3 of the studies included did not blind their assessors or
subjects to group allocation, with 3 others not specifying blinding conditions. Subjects from Louie
et al. 2021 and Palmcrantz et al. 2021 underwent more sessions in the RAGT group than the CGT,
indicating that dosage matching between groups may still be an issue. Stricter therapy protocols
and clarification on CGT practices are needed in future clinical trials (Louie et al. 2016). These
factors demonstrate that research bias may still be present. Future studies must continue to address
bias to increase validity of their findings.
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Limitations
There were several limitations to the present review. Only 2 databases were screened for
articles relevant to the inclusion criteria for this study. The screening process only comprised of
articles available through databases accessible through the Portland State University Library. Only
articles available or translated to English were included. There may be a multitude of randomized
clinical trials involving RAGT for stroke subjects that were not identified based on these screening
limitations.
Heterogeneity between studies was high across a variety of factors, such as subject
characteristics, physiotherapy protocol, devices used in RAGT groups, and assessment of outcome.
The definition of “subacute” and “chronic” stroke was highly inconsistent across all studies as
well. Full data on functional outcome measures of individual subjects was not readily available for
any of the studies included. Weighted means based on individual clinical average and median
values should only be viewed to generalize RAGT and CGT groups involving stroke subjects.
Significance between weighted means was not determined and most of the weighted means had
high standard deviations. Additionally, the presentation of solely median values in some studies
causes data interpretation of these weighted means to be even more challenging. Although studies
were compared based on opposing subject and study characteristics, there was a significant amount
of overlap between factors that could not be accounted for simply categorizing weighted means of
outcome measures. There were also a disproportionate number of studies falling under
categorizations of device type, stroke recovery phase, intervention length, and initial walking
ability of subjects. A full systematic, meta-analysis on these studies may determine heterogeneity
and address the wide array of potentially confounding factors. This study also did not observe

46
spatiotemporal kinematics and other functional outcome measurements that may elicit other
findings.

Concluding Statement

The results from the studies included in this review suggest that robotic-assisted gait
training of the lower limbs is a feasible and potentially beneficial solution for gait recovery in
stroke patients. A systematic meta-analysis should be considered to determine how the effects of
RAGT compare to CGT. Current clinical trials on the subject are addressing solutions to determine
appropriate usage of robotic gait trainers and proper intervention protocols for hemiparetic stroke
subjects. However, there are still a variety of research gaps that have yet to be considered in clinical
research on RAGT. Efforts should focus on the various considerations laid out in this article to
further enhance RAGT intervention protocols and increase research validity within this field.
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